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ABSTRACT

Malaria is the most prevalent vector-borne parasitic disease worldwide
and a major cause of death from infections. There is a great need to develop a
low cost vaccine for malaria to control transmission of infection and impact of
disease, due to the emergence of anti-malarial resistance. Two leading blood
stage malarial vaccine candidates are the apical membrane antigen-1 (AMA-1)
and the merozoite surface protein-1 (MSP-1).

The aim of this project is to

express malarial antigens in tobacco plants via plastid transformation and deliver
them by subcutaneous or oral gavage of minimally processed transplastomic
tissue to evaluate their efficacy to elicit an immune response and protect against
malarial infection. Transplastomic lines expressing the malarial antigens fused to
the transmucosal carrier Cholera toxin B subunit (CTB-AMA-1) and CTB-MSP-1
were generated. CTB-AMA-1 and CTB-MSP-1 accumulated up to 9.5% and 2%
of the total soluble protein, respectively. Chloroplast-derived CTB-AMA-1, CTBMSP-1, or both antigens were administered to BALB/c mice orally or by
subcutaneous injections.

The immune response in the experimental animals

compared to the control animals was found to be significant.

Using an

immunofluorescence assay (IFA) and immunoblot, anti-AMA-1 and anti-MSP-1
found in sera of immunized mice recognized the native parasite and the native
parasite protein, respectively. Anti-malarial antibodies inhibited parasite invasion
into erythrocytes by utilizing an in vitro parasite inhibition assay. Results of these
investigations may lead to a cost-effective malarial vaccine, much needed in
developing nations.
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INTRODUCTION
Malaria is a vector-borne protozoan disease and four different species of
the genus Plasmodium affects humans (P. falciparum, P. vivax, P. ovale, P.
malariae) with P. falciparum the most virulent species causing the majority of
morbidity and mortality across the world. More than 2 billion people are at risk
for malaria with approximately 500 million cases and 1 million deaths annually,
mainly in children in sub-Saharan Africa (Greenwood, Fidock et al. 2008;
Langhorne, Ndungu et al. 2008). Malaria has become a prominent public health
issue for the international health community and an effective malaria control
program is imperative (Greenwood, Bojang et al. 2005).
Plasmodium Life Cycle
Malaria parasites multiply in female Anopheles mosquitoes and are
transmitted to humans when a mosquito takes a blood meal.

Plasmodium

sporozoites, alongside saliva, enter the bloodstream, migrate to the liver, and
then enter hepatocytes where amplification lasts for 2 to 9 days, hence the exoerythrocytic cycle (Langhorne, Ndungu et al. 2008).

Malaria parasites

differentiate into thousands of merozoites, following rupture of liver cells, where
they invade RBCs and initiate the asexual erythrocytic stage of the life cycle.
The ring stage of parasite develops into a trophozoite and matures into
schizonts, which ruptures and releases merozoites approximately 48 and 72
hours, depending on the species of Plasmodium (Langhorne, Ndungu et al.
2008). The blood stage parasites are responsible for the clinical manifestations
such as fever and severe malaria.

Some parasites develop into sexual
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erythrocytic

male

(microgametocytes)

and

female

(macrogametocytes)

gametocytes, which fuse to form an ookinete, after a mosquito takes a blood
meal and ingests the gametocytes.

The sporogonic cycle begins when the

parasites multiply in the mosquito gut. Ookinetes develop into oocysts in the
midgut wall of the mosquito, which grow, rupture, and release sporozoites. Once
the sporozoites migrate to the mosquito’s salivary glands, they are ready to infect
a new human host to continue the malaria life cycle.
Clinical Manifestations of Malaria
The most common symptoms of malaria include flu-like illness such as
fever, shivering, vomiting, nausea, joint pain, muscle aches, and headaches.
The classical symptom of malaria is the sudden coldness with shivering followed
by fever and then sweating persisting six to ten hours that occurs in cycles due
the asexual erythrocytic stage of the Plasmodium spp. life cycle.

Other

symptoms experienced by malaria patients include dizziness, malaise, myalgia,
abdominal pain, mild diarrhea, and dry cough. The causative organism of severe
malaria is P. falciparum and consequences include coma and death if untreated.
Other complications of severe malaria may occur and include splenomegaly,
cerebral ischemia, hepatomegaly, hypoglycemia, hemoglobinuria, renal failure,
pulmonary edmea, and acidosis. Young children and pregnant women are most
vulnerable to severe malaria along with individuals with no or decreased
immunity. Severe malaria is considered a medical emergency and should be
treated urgently because it can rapidly progress to death within hours or days
(Trampuz, Jereb et al. 2003).
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Diagnosis and Treatment of Malaria
The number of cases of malaria is increasing and drug resistance is
common so prompt diagnosis is essential to reduce morbidity and mortality
(Yamey 2004). Clinical diagnosis of patients involve examination of symptoms
but the “gold standard” from a laboratory perspective is examining a blood smear
stained with Geimsa stain via microscopic examination (Icke, Davis et al. 2005).
If a microscope and staining reagents are not available and lack of quality
microscopy, modern antigen detection kits such as a “dipstick” and molecular
techniques can be used as alternative in diagnosis (Greenwood, Bojang et al.
2005; Icke, Davis et al. 2005). Several issues have evolved with using antigen
detection kits and molecular practices such as cost-benefit ratio, accuracy of
results, and adequate performance in field conditions.
Malaria needs to be recognized without delay in order to treat the patient
and prevent further disease transmission.

Treatment of malaria can be

conducted without hospitalization but if severe malaria persists hospitalization
should be advised if possible.

Several antimalarial drugs are available for

treatment such as chloroquine, sulfadoxine-pyrimethamine, mefloquine, quinine,
artemisinin and doxycycline but combination treatment is ideal. The combination
of drugs is preferred because different modes of action are included to hopefully
inhibit the emergence of drug resistant parasites (Greenwood, Bojang et al.
2005). Many factors should be considered when treating a patient with malaria
such as species of infecting parasite, demographic region, cost, pregnancy, preexisting conditions, and drug allergies.
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Need for an Antimalarial Vaccine
Preventing mosquito bites with mosquito nets or insect repellents,
spraying insecticides, can reduce malaria transmission or expensive prophylactic
drugs but resurgence of the parasite continues.

The causes of resurgence

includes drug resistance to common antimalarials such as chloroquine,
antifolates, sulfadoxine, and artemisin; mosquito’s resistance to widely used
insecticides, pharmaceutical’s lack of interest in developing new drugs,
implementing effective control measures, increase of tourism, and migration of
non-immune populations to malaria endemic areas (Aide, Bassat et al. 2007;
Hyde 2007). A traditional public health tool to effectively reduce the tremendous
disease burden would be to develop an efficacious antimalarial vaccine (Doolan
and Stewart 2007). Vaccination is one of the most effective means of preventing
disease transmission, cost-effective in reducing new infections, and is easily
administered. Many concerns arise when developing an effective vaccine such
as complexity of antigens Plasmodium presents throughout the different stages
of its life cycle, high polymorphism among parasitic proteins, no appropriate
animal model to test the efficacy of a vaccine, high cost of designing a vaccine,
and length of vaccine development before it can be marketed by pharmaceutical
companies (Aide, Bassat et al. 2007). Currently, there is no licensed effective
vaccine for the prevention of malaria. The desirable vaccine to prevent malaria
progression would consist of multi-antigens from different phases of the life cycle.
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Malaria Vaccines are Feasible
There are four main arguments supporting the belief that a malaria
vaccine is feasible (Aide, Bassat et al. 2007). Individuals living in endemic areas
progressively exhibit naturally acquired immunity by developing partial immunity
against severe malaria (Gupta, Snow et al. 1999). Individuals may still become
infected with malaria but clinical manifestations and symptoms may be nonexistent due to suppression of parasitemia to undetectable levels (Webster and
Hill 2003). Passive transfer of antibodies from either immune malaria patients or
maternal transmission during pregnancy has protected patients exposed to the
parasite (Sabchareon, Burnouf et al. 1991) or newborn infants (Ballou, ArevaloHerrera et al. 2004), respectively. In the 1970s, experiments were carried out on
non-immune volunteers that were exposed to UV irradiated-weakened
sporozoites and re-challenged by normal sporozoites with 90% of cases
exhibiting short-lived immunity (Rieckmann, Beaudoin et al. 1979).

Several

studies have reported the efficacy of recent development of protective malaria
vaccine candidates in humans (Greenwood, Fidock et al. 2008; Maher 2008).
Candidates for Malaria Vaccine
Due to the complexity of the malaria life cycle, vaccines can be targeted to
the different stages beginning with the initial stage, exo-erythrocyctic.

The

ultimate goal in vaccine development targeting the exo-erythrocyctic stage are
the sporozoites and liver stage parasites to completely prevent infection
(Greenwood, Fidock et al. 2008) by protecting against invasion of hepatocytes or
inhibiting parasite development in hepatocytes. Antibodies elicited at this stage
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would either kill the sporozoite or block hepatocyte invasion. Disrupting parasite
development in infected hepatocytes would involve cytotoxic T-lymphocyte
mediated lysis. The earliest and now the most advanced pre-erythrocytic studied
vaccine candidate utilizes CSP as a target because it is the most abundant
surface antigen at this stage (Greenwood, Bojang et al. 2005). Current vaccine
trials utilizing CSP consists of a hybrid with the hepatitis-B surface antigen and a
three-component adjuvant, AS02, known as RTS,S/AS02A but has provided only
short-term protection (Greenwood, Bojang et al. 2005). Other antigens in clinical
trials include TRAP and LSA but with disappointing results (Maher 2008).
Another strategy in vaccine development could target the second phase of
the life cycle, erythrocytic, also known as the asexual blood phase. Vaccines
targeted at this stage are designed to prevent disease not infection by reducing
the number of blood stage parasites (Greenwood, Fidock et al. 2008).

The

vaccine could either prevent merozoite multiplication or invasion of RBCs, with
current research mainly focusing on antigens involved in erythrocyte invasion
(Greenwood, Bojang et al. 2005).

Antibodies can be elicited to agglutinate

merozoites before schizont rupture or blocking invasion of RBCs. Current clinical
trials are under way looking at several blood stage candidates such as AMA-1,
MSP-1, and RESA (Greenwood, Bojang et al. 2005; Maher 2008).
A final approach in vaccine development is to target the last stage in
development, referred as the sexual phase.

Vaccines, also known as

transmission-blocking, targeted at this stage are important in reducing parasite
transmission to others by preventing feeding mosquitoes from becoming infected
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or sexual fusion of gametocytes in the midgut of the mosquito (Greenwood,
Bojang et al. 2005; Saxena, Wu et al. 2007). This is an indirect way of providing
protection but it helps in reducing disease transmission in the community
(Greenwood, Fidock et al. 2008). Antibodies can be induced to kill gametocytes,
interfere with fertilization of gametocytes, transformation of the zygote into
ookinete, or egress of ookinetes into viable sporozoites. The approach of using a
transmission-blocking vaccine is usually combined with other vaccines targeting
other stages (Greenwood, Fidock et al. 2008).

Current research on

transmission-blocking vaccine candidates include Pfs 25/28, Pfs 48/45, and Pfs
230 (Greenwood, Bojang et al. 2005; Saxena, Wu et al. 2007) and could play a
role in reducing transmission in the population.
Apical Membrane Antigen-1 (AMA-1)
AMA-1 is a leading asexual blood-stage vaccine candidate (Good, Kaslow
et al. 1998) because it plays a crucial role in invasion of Plasmodium parasites.
AMA-1 is a type I integral membrane protein (Remarque, Faber et al. 2008) and
initially traffricked to micronemes as an 83 kDa precursor protein and
proteolytically processed to PfAMA-166 before exportation to the merozoite
surface. AMA-1 has been implicated as playing a function in reorienting with the
merozoite as the apical organelles and RBC membrane align during invasion
(Mitchell, Thomas et al. 2004). Animal and in vitro studies support the crucial
role for AMA-1 during invasion of RBCs such as anti-AMA-1 antibodies inhibiting
invasion via growth inhibition assays (Hodder, Crewther et al. 2001), antibodymediated inhibition of antigen processing (Dutta, Haynes et al. 2003), anti-AMA-1
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antibodies found in exposed individuals via sero-epidemiological surveys
(Thomas, Trape et al. 1994), and AMA-1 has conferred protection in
immunization studies (Narum, Ogun et al. 2000). A critical issue with the using
AMA-1 as a vaccine candidate is it is highly polymorphic (Healer, Murphy et al.
2004) and this reduces susceptibility to the action of inhibitory antibodies. Even
though AMA-1 exhibits high polymorphism the C-terminal region is highly
conserved and can be blocked by inhibitory antibodies. AMA-1 is not only found
in asexual blood stage merozoites but also expressed by sporozoites and liver
stage merozoites (Remarque, Faber et al. 2008). Targeting AMA-1 as a vaccine
candidate not only can reduce the risk of malaria infection causing clinical
disease but also the possibilities of cellular immunity may be stimulated and
reduction in exo-erythrocytic viability. The current literature definitely supports
the idea of AMA-1 and its potential as a vaccine candidate.
Merozoite Surface Antigen-1 (MSP-1)
MSP-1 is another leading asexual blood stage vaccine candidate
(Siddiqui, Tam et al. 1987) and is proposed to play a role in parasite invasion of
RBCs (Blackman, Heidrich et al. 1990).

MSP-1 is a 195-kDa glycoprotein

(Mehrizi, Zakeri et al. 2008) found on the merozoite surface, which undergoes
two proteolytic cleavages for entry into RBCs. The first cleavage occurs when
the merozoite is released from an infected RBC resulting in four polypeptide
fragments (83, 30, 38, and 42 kDa) and the second cleavage occurs during
invasion of a RBC and involves the C-terminal 42 kDa fragment that is cleaved
into 33 and 19 kDa polypeptides (Mehrizi, Zakeri et al. 2008). MSP-119 stays
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anchored to the merozoite surface via a GPI tail when RBC invasion takes place
(Chenet, Branch et al. 2008). The C-terminal portion of MSP-119 is a target of
some monoclonal antibodies because they inhibit the growth of parasites in vitro
(Uthaipibull, Aufiero et al. 2001) and has shown to provide protective immunity
(O'Donnell, de Koning-Ward et al. 2001). Vaccines based on the C-terminal
region of MSP-1 including MSP-142 and MSP-119 have provided protection after
parasite challenge in Aotus monkeys (Kumar, Yadava et al. 1995; Chang, Case
et al. 1996), antibodies have been shown to inhibit RBC invasion and parasite
growth (Blackman, Heidrich et al. 1990; Chang, Case et al. 1996), and anti-MSP119 has been correlated to clinical immunity with reduced parasite numbers and
febrile illness (Branch, Udhayakumar et al. 1998). A limiting factor in asexual
stage vaccine development is that the C-terminal fragments of MSP-1 parasites
isolated in different geographical areas have displayed sequence variation
(Mehrizi, Zakeri et al. 2008). Previous studies have provided the insight of using
MSP-1 as a potential malaria vaccine candidate.
The Use of Plants for an Anti-Malarial Vaccine
There needs to be alternative approach in preparing an effective vaccine
to enhance expression levels and potentially protection against malaria infection.
Commonly used expression systems such as yeast, bacteria, mammalian cells,
and baculovirus have expressed several malarial antigens but with the era of
biotechnology other expression systems are being developed. Plants could be
considered as an optimal expression system because they can reduce cost due
to the expense of fermentation, purification, processing, cold storage,
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transportation, and delivery (Ruhlman, Ahangari et al. 2007; Arlen, Singleton et
al. 2008). The genetic manipulation of tobacco is highly achievable and yields
large biomass and the success could be extended to other edible crops such as
carrot, tomato, or lettuce.

Oral delivery of plant-derived vaccines has been

shown to induce both mucosal and systemic immunity (Nochi, Takagi et al. 2007;
Verma and Daniell 2007). The genetic engineering of plants could establish a
cost-effective approach in vaccine development to poor, developing countries
where malaria infection is most severe.
Advantages of Chloroplast Genetic Engineering
Many crop species have been genetically modified to express human
therapeutic proteins via the nuclear genome but expression levels of the foreign
protein are inefficient to purify or oral deliver. Chloroplast genetic engineering
has been a targeted approach to overcome the concerns of using nuclear
transformation such as high level expression of foreign proteins due to thousands
of genomes per cell (De Cosa, Moar et al. 2001; Daniell, Khan et al. 2002), gene
containment (Daniell 2002; Daniell 2007), gene silencing and position effect (De
Cosa, Moar et al. 2001), pleiotropic effects (Daniell, Lee et al. 2001), and multigene expression (De Cosa, Moar et al. 2001; Quesada-Vargas, Ruiz et al. 2005)
in a single transformation event.

Chloroplast transformation technology has

contributed in the medical advancement such as expressing proteins in disease
resistance (DeGray, Rajasekaran et al. 2001), biopharmaceuticals (Staub, Garcia
et al. 2000; Fernandez-San Millan, Mingo-Castel et al. 2003; Arlen, Falconer et
al. 2007; Ruhlman, Ahangari et al. 2007), and vaccines (Daniell, Streatfield et al.
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2001; Kamarajugadda and Daniell 2006; Arlen, Singleton et al. 2008); and in
agriculture such as herbicide (Daniell, Datta et al. 1998) and insect resistance
(Kota, Daniell et al. 1999), and phytoremediation of toxic metals (Ruiz, Hussein
et al. 2003; Hussein, Ruiz et al. 2007) in transgenic plants. Genetic engineering
is achieved by stably integrating the flanking sequences of the foreign gene
through homologous recombination with the intergenic regions of the chloroplast
genome (Kumar and Daniell 2004).

The use of plastid transformation and

chloroplast genetic engineering has allowed the expression of foreign genes at a
level that is optimal for the oral delivery of vaccines.
Vaccine Antigens Expressed via the Chloroplast Genome
Several vaccine antigens have been expressed using the approach of
chloroplast genetic engineering (Kamarajugadda and Daniell 2006). The many
advantages of expressing antigens in the chloroplast listed above supports the
current rationale of producing transgenic lines expressing the vaccine antigen of
interest. Numerous vaccine antigens expressed via the chloroplast are targeted
against bacterial, viral, and protozoan pathogens such as the plague F1-V fusion
antigen (Arlen, Singleton et al. 2008), Entamoeba histolytica (Chebolu and
Daniell 2007) anthrax protective antigen of Bacillus anthracis (Watson, Koya et
al. 2004; Koya, Moayeri et al. 2005), VP6 protein of rotavirus (Birch-Machin,
Newell et al. 2004), 2L21 peptide from the virulent canine parvovirus (CPV)
(Molina, Hervas-Stubbs et al. 2004), and CTB for cholera (Daniell, Lee et al.
2001). The expression levels of the PA of anthrax was up to 14.2% of TSP and
subcutaneous immunization of mice with partially purified chloroplast-derived PA
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resulted in 100% survival after challenge with lethal doses of anthrax toxin (Koya,
Moayeri et al. 2005).

The expression levels of the F1-V fusion antigen

accumulated up to 14.8% of TSP and after challenge with aerosolized Yersinia
pestis all control animals died in three days and 33% of animals receiving boosts
of subcutaneous injections of F1-V and 88% of mice receiving oral boosts of F1V were protected (Arlen, Singleton et al. 2008).

This finding brings hope of

utilizing the approach of chloroplast technology and oral-deliverable, costeffective vaccines closer to reality.
Cholera Toxin B Subunit (CTB)
The Gram-negative bacteria Vibrio cholerae secretes an enterotoxin
known as cholera toxin. CT is oligomer made up of six proteins AB5 consisting of
one toxic 27 kDa A subunit and five non-toxic B subunits each weighing 11.6 kDa
(Daniell, Lee et al. 2001).

This hexameric complex facilitates entry into the

mucosal epithelia of the intestine via CTB and the GM1 ganglioside receptors
(Daniell, Lee et al. 2001).

GM1 gangliosides are found on the gut epithelial

surface and it is known CTB to have a high affinity to these glycosphingolipids
(Mor, Gomez-Lim et al. 1998). CTB is known when given orally to be a safe,
potent, mucosal immunogen and adjuvant (Holmgren, Lycke et al. 1993). CTB
has the potential to enhance the immune response when coupled to other
pathogenic antigens (Daniell, Lee et al. 2001). A previous study used CTB-GFP
plants and oral administered the transgenic leaf material to mice and observed
CTB in the intestinal wall and GFP fluorescence in mouse intestinal mucosa,
liver, and spleen (Limaye, Koya et al. 2006) This opens the possibility of oral
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deliverable human therapeutic proteins via receptor-mediated oral delivery
(Ruhlman, Ahangari et al. 2007).
Bioencapsulation for Oral Delivery
A critical issue arises with the oral delivery of vaccine antigens into the
body. The antigen delivered needs to be intact and retain its biological activity
and withstand the digestive enzymes present in the stomach. Bioencapsulation
is the process of plant cells’ ability to protect an oral-delivered protein from acid
digestion (Walmsley and Arntzen 2000). Oral delivery of vaccine antigens needs
to cross the mucosal barrier effectively to provide protection in the event of the
immune system encountering the pathogen. Previous reports show that GFP
fused with transmucosal carrier CTB was bioencapsulated because following oral
administration of CTB-GFP leaf material both CTB and GFP was found in mouse
intestinal cells (Limaye, Koya et al. 2006). GFP but not CTB was present in the
liver of mice after oral delivery indicating it was protected from the digestive
enzymes of the stomach.

The role of receptor-mediated oral delivery and

bioencapsulation provides insight in producing low-cost vaccines that deliver
vaccine antigens effectively.
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RATIONALE AND APPROACH
The primary objective of this project is to express and characterize the
malarial antigens CTB-AMA-1 and CTB-MSP-1 via the chloroplast genome and
evaluate the immunogenicity of the chloroplast derived antigens. The novelty of
this project is the approach of delivering the chloroplast-derived CTB-malarial
antigens via oral delivery and comparing the immunogenicity to the typical route
of administration of vaccines, through injection. To achieve these objectives,
malarial gene products need to be cloned into pLD-UTR for expression in plants.
Using particle bombardment, transgenic lines need to be obtained to express the
chloroplast-derived CTB-malarial antigens.

The chloroplast-derived proteins

need to be quantified for enrichment for subcutaneous injection and delivery to
rodents via oral gavage. The immunogenicity of the mouse titers needs to be
determined via ELISAs for the comparison of subcutaneous injection versus oral
delivery. The antibodies present in the immunized mouse sera will be tested with
immunoblot and IFA analysis to determine recognition of native parasite protein
and native parasite, respectively. If the antigens are immunogenic, they will be
tested to determine their ability inhibit parasite invasion into RBCs.
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MATERIALS AND METHODS
Amplification of AMA-1 and MSP-1 in Asexual Stages and Cloning
Based on the C-terminal regions of AMA-1 and MSP-1 (Pan, Huang et al.
2004), forward and reverse primers were designed to amplify the gene. The total
RNA used for RT-PCR was isolated prior (stored at -80°C) by harvesting an
asynchronous 3D7 P. falciparum parasite culture with 0.05% saponin lysis and
isolating total RNA by using the RNAgents Total RNA Isolation System
(Promega). The forward primers designed were (5’-CCCGGGGCCAAGAAAAAGAAGAGCTTTGTCCCATCCCAT-3’) with a SmaI site and Furin Cleavage site
(Arg-Lys-Arg-Arg) and (5’-CCCGGGGCCAATTTCACAACACCAATG-3’) with a
SmaI site for AMA-1 and MSP-1, respectively. The reverse primers designed
were (5’-CGGCGGCCGCTTTCATGTTATCATAAGTTG-3’) and (5’-ATAAGAATGCGGCCGCTTAGTTAGAGGAACTGCAGAAAA-TAC-3’) with a NotI site for
AMA-1 and MSP-1, respectively.

The StrataScript one-tube RT-PCR system

(Stratagene) with Easy-ATM High-Fidelity PCR Cloning Enzyme was used to
reverse transcribe and amplify the genes using 200 ng of total RNA and the
gene-specific primers. RT-PCR cycling conditions were as follows: 1 cycle of
reverse transcription at 42°C for 30 minutes followed by transcriptase enzyme
inactivation at 95°C for 30 seconds; 5 cycles of denaturation at 95°C for 30
seconds, annealing at 50°C for 30 seconds and extension at 68°C for 6 minutes;
35 cycles at 95°C for 30 seconds, 58°C for 30 seconds and 65°C for 6 minutes
and 1 cycle at 65°C for 10 minutes. 5 µL of RT-PCR products were analyzed by
electrophoresis on a 0.8% agarose gel and visualized by the Gel Doc 2000 (Bio
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Rad). The remainder of the RT-PCR product was purified with the QIAquick
PCR Purification Kit (Qiagen) and confirmed by a 0.8% agarose gel. The genes
were cloned into the pGEMT Easy Vector (Promega) and the presence of the
insert was confirmed by digestion with EcoRI and gel electrophoresis. The DNA
was sent to the University of Florida: DNA Sequencing (ICBR: The Biotechnology
Program) facility for sequencing. Accuracy of the insert sequence was confirmed
by using the DNA STAR SeqMan program. The FC AMA-1 and MSP-1 genes
were subcloned into the pBSK+ (Stratagene) vector by using the SmaI and NotI
restriction sites.
Amplification and Cloning of CTB
Template DNA containing the CTB gene was provided by Dr. Daniell’s lab.
The CTB gene was amplified via PCR with a forward primer (5’CCGCTCGAGCATATGACACCTCAAAATATTACT-3’) with XhoI and NdeI sites
and a reverse primer (5’-CCCGGGCCATTTGCCATACTAATTGC-3’) with a SmaI
site. The CTB gene was cloned into the pGEMT Easy Vector (Promega) and the
sequence was confirmed. CTB was subcloned into the pBSK+ vector using the
XhoI and SmaI restriction sites.

The pBSK+ CTB, pBSK+ FC AMA-1, and

pBSK+ MSP-1 were digested with SmaI and NotI restriction enzymes and the FC
AMA-1 and MSP-1 genes were ligated into the pBSK+ CTB plasmid to complete
the fusion genes: CTB FC AMA-1 and CTB MSP-1.

16

Chloroplast Plasmid Construction
The CTB FC AMA-1 and CTB MSP-1 transgenes in the pBSK+ vector
were cut with NdeI and NotI restriction enzymes and ligated into the pLD-UTR
vector

with

T4

ligase

(New

England

BioLabs)

and

transformed

into

supercompetent E. coli XL-10 Gold cells. The figure below demonstrates the
proposed orientation of the transgene into the chloroplast vector.

Figure 1: Chloroplast pLD-UTR CTB-Malarial Antigens (not drawn to scale)
Following transformation of chloroplast vector constructs into E. coli,
colonies were selected and grown overnight in 5 mL of LB broth and 5 µL of
ampillicin (100 mg/mL).

The DNA was isolated by using the QIAprep Spin

Miniprep Kit (Qiagen), digested with NdeI and NotI restriction enzymes, and
analyzed by a 0.8% agarose gel. A positive clone containing the chloroplast
vector construct was obtained from the glycerol stock and grown overnight. The
chloroplast plasmid DNA was purified with the QIAprep Plasmid Maxi Kit
(Qiagen) and the DNA was analyzed by gel electrophoresis on a 0.8% agarose
gel.
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Generation of Transgenic Plants
Preparation of Gold Particles
A mixture of 50 mg of gold particles and 1 mL of 100% ethanol was
vortexed for two minutes and centrifuged at 10,000 x g for three minutes in a 1.5
mL eppendorf tube. The supernatant was discarded and the gold particles were
resuspended in 1 mL of 70% ethanol for one minute. The suspension was left at
room temperature for fifteen minutes with mixing intermittently. Centrifuging at
5,000 x g for two minutes pelleted the gold particles and the supernatant was
discarded. The gold particles were vortexed with 1 mL of sterile distilled water
and incubated at room temperature for one minute and centrifuged at 5,000 x g
for two minutes. The steps to wash the gold particles with sterile water were
repeated three times (Kumar and Daniell 2004).

The gold particles were

resuspended in 1 mL of sterile 50% glycerol and stored on ice until use.
50 µL of gold particles was removed from the stock and transferred into a
1.5 mL microcentrifuge tube along with 10 µg of plasmid DNA. To ensure proper
binding of DNA to the gold particles 50 µL of 2.5 M CaCl2 and 20 µL of 0.1 M
spermidine-free base was added. The mixture was vortexed for twenty minutes
at 4°C and the DNA-coated gold particles were centrifuged at 10,000 x g for one
minute. The supernatant was removed and the pellet was washed four times in
200 µL of absolute alcohol. The DNA-coated gold particles were resuspended in
50 µL of 100% ethanol.

10 µL of vortexed DNA-coated gold particles were

loaded onto sterile macrocarriers and allowed to air dry in the laminar air flow
hood.
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Bombardment of Leaf Tissue
The bombardment was performed under sterile conditions with all
equipment including the gene gun (Bio-Rad PDS-1000/He) sterilized with 95%
ethanol. Green healthy leaves from the in vitro tobacco plant Nicotiana tabacum
variety Petit Havana were cut from young plants and placed with the adaxial side
facing up on autoclaved Whatman filter paper on the top of solidified RMOP
medium. The macrocarrier with the DNA-gold coated particles were placed on
the macrocarrier holders. The bombardment was performed at 1,100 psi and 28
Hg.

After the bombardment, the transformed leaves were covered with

aluminum foil and kept in the dark for 48 hours at room temperature (Kumar and
Daniell 2004).
Regeneration and Selection of Transplastomic Shoots
After 48 hours, the leaves were cut into 5x5 mm2 pieces and transferred to
RMOP media (one pack of MS basal salt mixture, 30 g of sucrose, 100 mg myoinositol, 1 mL of 1 mg/mL BAP, 100 µL of 1 mg/mL NAA, 1 mL of thiamine
hydrochloride to 1 L of sterile distilled water and adjusted to pH 5.8 using 1N
KOH; 6g of phytagar was added to media to solidification; autoclaved and cooled
before pouring into plates) containing 500 µg/mL of spectinomycin with the
bombarded side in contact with medium. The Petri dish was sealed with parafilm
and kept in the culture room until putative transgenic shoots appear. Confirmed
positive transgenic lines by PCR analysis were subjected to second round of
selection to achieve homoplasmy. After four weeks on secondary selection, the
shoots were transferred to MSO media (one packet of MS basal salt mixture and
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30 g of sucrose to 1 L of sterile distilled water; prepared to pH of 5.8 using 1N
KOH; 6 g of phytagar) with 500 µg/mL spectinomycin. This accounts for the third
round of selection and rooting.
Isolation of Plant DNA and Confirmation of Transgene Integration
Before proceeding to the next round of selection, 100 mg of leaf material
was harvested from putative transplastomic shoots. The QIAprep DNeasy Plant
Mini Kit (Qiagen) was used to isolate plant genomic DNA, following the
manufacturer’s protocol. The procedure yields approximately 20-30 µg of DNA
and the isolated DNA was used for PCR analysis. PCR was used to confirm
transgene cassette integration into the chloroplast genome by the primer pair 3P
(5’AAAACCCGTCCTCEGTTCGGATTGC-3’) and 3M (5’CCGCGTTGTTTCATCAAGCCTTACG-3’) (Daniell, Ruiz et al. 2005). The integration of the gene of
interest

was

confirmed

by

PCR

using

the

primer

pair

5P

(5’-

CTGTAGAAGTCACCATTGTTGTGC-3’) and 2M (5’-TGACTGCCCACCTGAGAGCGGACA-3’) (Daniell, Ruiz et al. 2005). DNA isolated from wild type Petit
Havana was used as the negative control and DNA isolated from known
transgenic plant material was used as the positive control. For PCR analysis, 50
µL of reaction volume was prepared in a 0.2 mL PCR tube: 1µL of 100 ng/µL
genomic DNA, 5 µL of 10X PCR reaction buffer, 4 µL of 2.5 mM dNTP, 1 µL of
3P and 3M primers (or 5P and 2M primers), 1 µL of Taq DNA polymerase, and
sterile distilled water to make up the total volume. The initial denaturation was
set at 94° for 5 minutes and amplification was carried out for thirty cycles of the
following program: 94°C for 1 minute (denaturation), 60°C for one minute
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(annealing), and 72°C for 2 minutes (extension). Final extension of ten minutes
at 72°C was carried at the end of PCR.

To examine the PCR product via

agarose gel electrophoresis, 5 µL of was loaded, along with controls, into a 0.8%
agarose gel and visualized by the gel doc.
Southern Blot Analysis to Identify Homoplasmic Plants
Isolation of Plant Genomic DNA
Leaf material from transgenic and non-transgenic plants was removed
with aseptic technique from the in vitro greenhouse and ground with liquid
nitrogen into 100 mg of a fine powder. Previously made and stored at 65°C, 1
mL of DNA extraction buffer (Tris-HCl pH8, EDTA, NaCl, CTAB, BME up to 10
mL of water) was added to the leaf material and incubated at 65°C for thirty
minutes with gentle mixing every five to eight minutes.

667 µL of (48:2)

chloroform:isoamyl alcohol was added to the homogenate with gentle inverting
for one minute followed by centrifugation at 10,000 rpm for ten minutes. The
supernatant was collected and placed into new tubes and 667 µL of ice, cold
isopropyl alcohol was added with gentle mixing to precipitate nucleic acid. A
visible, dense clump was seen and centrifuged for ten minutes at 10,000 rpm.
The nucleic acid was washed twice with 70% ethanol and allowed to air dry at
room temperature followed by further drying with the DNA 110 speed vac
(Savant Instruments, Inc.) for five minutes. The pellet was dissolved in 500 µL of
0.1X TE (1mM Tris-HCl (pH 8) + 0.1mM EDTA (pH 8)) containing 0.1 µg/µL
RNase and incubated at 37°C for thirty minutes.
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500 µL of (24:25:1) of

chloroform:phenol:isoamyl alcohol was added and mixed thoroughly to visualize
three layers and centrifuged for fifteen minutes at 12,000 rpm. The upper layer
containing the DNA was removed and placed into new tubes and the same
volume of chloroform was added to remove phenol.

The tube was mixed

thoroughly and centrifuged for fifteen minutes at 14,000 rpm. Two layers were
visualized and the top layer containing DNA was transferred to new tubes. 1 mL
of 100% chilled ethanol and 33 µL (1/10th volume of DNA) of 3M Na Acetate, pH
5.2 was added to allow precipitation of DNA. The reaction was kept at -20°C for
one hour and centrifuged for ten minutes at 14,000 rpm. The supernatant was
decanted very slowly with a visible white pellet remaining.

The pellet was

washed with 70% ethanol and centrifuged for ten minutes at 14,000 rpm. The
pellet was dried with a DNA 110 speed vac (Savant Instruments, Inc.) for five
minutes to remove remaining ethanol and dissolved in 100 or 200 µL 0.1X TE
(1mM Tris-HCl (pH 8) + 0.1mM EDTA (pH 8)), depending on the pellet size. The
genomic samples were loaded on a 0.8% agarose gel to visualize the bands.
The concentration of the DNA was determined by a spectrophotometer.
Restriction Digestion of Genomic DNA
The transgenic and untransformed samples containing equal amounts of
DNA were digested with ApaI in a reaction containing: 1.5 µg of DNA, 4 µL of
10X BSA, 4 µL of 10X Buffer 4 (New England Biolabs), 2 µL of ApaI (New
England Biolabs), and sterile distilled H20 to make up the volume of 40 µL. The
reaction was incubated overnight at 37°C.
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Agarose Electrophoresis and DNA Transfer
Each of the 40 µL reaction volume samples was loaded on a 0.8%
agarose gel and electrophoresis was run for 3 hours at 100 volts. The gel was
visualized with a fluorescent ruler. The gel was depurinated with 0.3N HCl for
ten minutes (until the color of the dye became yellow) and removed. This was
followed by immersing the gel into Hybridization Denaturing Solution (5 PRIME –
3PRIME) for thirty minutes followed by a wash with sterile H20. The gel was
immersed with Hybridization Neutralization Solution (5 PRIME – 3 PRIME) for
thirty minutes followed by a wash in transfer buffer (2X SSC, Eppendorf) for 5
minutes. The membrane (S & S Nytran: SuperCharge, Schleicher & Schuell)
was immersed in sterile H20 for fifteen minutes and left in transfer buffer until use.
The transfer of DNA from the agarose gel to membrane utilized the Turboblotter
(Rapid Downward Transfer System/Buffer Tray, Schleicher & Schuell) protocol.
Twenty sheets of dry GB004 paper, followed by four sheets of dry GB002, and
one sheet of prewet, in transfer buffer, GB002 was placed in the stack tray. The
prewet transfer membrane was placed on the stack followed by the agarose gel
on top. A rolling pin was used to remove any air bubbles that were present. The
top of the gel was wet with the application of transfer buffer and three sheets of
prewet GB002 paper was placed on top. The buffer tray was attached to the
stack tray and filled with 125 mL of transfer buffer. The wick was placed on top
of the stack so the ends would drape into the buffer tray. The wick cover was
placed on top to prevent evaporation and the transfer continued overnight at
room temperature. The following day, the membrane was marked with a pencil
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and rinsed with transfer buffer for five minutes. The membrane was placed on
chromatography paper and allowed to air dry. The membrane was cross-linked
using the UV Stratalinker 2400 (Stratagene) at the setting autocrosslink and
stored at a dry place until further use.
Generation of Probes
The following PCR reaction was set up for the amplification of the 2P2M
flanking sequence probe with the 2P primer (5’-GCGCCTGACCCTGAGATGTGGATCAT-3’) and 2M primer (5’-TGACTGCCCAACCTGAGAGCGGACA -3’): 1 µL
of DNA, 5 µL of 10X Buffer, 2.5 µL of MgCl2, 1 µL of dNTP, 1 µL of 2P primer, 1
µL of 2M primer, 1 µL Taq polymerase, and 37.5 µL of sterile H20. The initial
denaturation was set at 94° for 5 minutes and amplification was carried out for
twenty-nine cycles of the following program: 94°C for 30 seconds (denaturation),
61°C for 30 seconds (annealing), and 72°C for 1 minute and 30 seconds
(extension). Final extension of seven minutes at 72°C was carried at the end of
PCR.

The 50 µL PCR reaction was loaded into a 0.8% agarose gel and

visualized with the Bio Rad Gel Doc 2000. The bands were excised and gel
extracted with the QIAquick Gel Extraction Kit (Qiagen) by following the
manufacture’s protocol and eluting with 35 µL of Buffer EB.
Prehybridization of Membrane
Into the hybridization bottle, the membrane was placed with the side
exposed to DNA facing inwards and 20 mL of prehybridization solution (36.5 mL
of sterile water, 10 mL of 20X SSC, 2.5 mL of 100X Denhardt’s (6% Ficoll, 6%
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polyvinylpyrrolidone, 6% BSA), 500 µL of 10% NaPPi, and 500 µL of 10% SDS)
was added and incubated at 65°C with the Hybridiser HB-1D (Techne).
Sonicated salmon sperm DNA (10 mg/mL) (Stratagene) was boiled for minutes
and 500 µL was added into the hybridization bottle. The pre hybridization of the
membrane incubated at 65°C for four hours.
Probe Labeling and Purification
The PRIME-It Random Primer Labeling Kit (Stratagene) protocol was
followed to label the radioactive probe. In a clean microcentrifuge tube: 20 ng of
the flanking probe, 10 µL of random oligonucleotide primers, and up to 23 µL of
sterile H20 was added and boiled for five minutes.

The mixture was briefly

centrifuged at room temperature. The following was added in order: 10 µL of 5X
ATP buffer, 5 µL of Redivue (Alpha-32P) DATP, and 1 µL of Exo (-) Klenow
(5U/µL) and mixed by stirring. The mixture was heated for fifteen minutes at
37°C followed by adding 2 µL of stop mix. A NucTrap probe purification column
(Stratagene) was placed in a push column device and a clean microcentrifuge
tube containing 100 µL of salmon sperm DNA was placed below. 80 µL of 1X
STE was injected into the column with a syringe and collected into the
microcentrifuge tube.

The radiolabeled probe was added to the column and

pushed through with a syringe followed by 80 µL of 1X STE. The syringe was
applied to the column once more and 300 µL of 1X STE was added to the
purified probe.
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Hybridization and Washing of Membrane
The purified probe was boiled for five minutes and added to the
hybridization bottle with a sterile transfer pipette and allowed to hybridize with the
membrane overnight at 65°C. The following day, the membrane was washed
twice, five minutes each with wash buffer #1 (2X SSC, 0.1% SDS, and 0.1%
NaPPi) followed by washing with wash buffer #2 (0.2X SSC, 0.1% SDS, and
0.1% NaPPi) four times, fifteen minutes each. The wash buffer was discarded
into the P32 waste and the membrane was allowed to air dry behind the plastic
shield. The radioactive membrane was wrapped with saran wrap and a ladder
(Stratagene) was placed on front.
Autoradiography
The film cassette along with the hybridized blot was taken to the dark
room and under safe, red light the blot was placed faced down onto the
intensifier screen and the BIOMAX MS Film: Maximum Sensitivity (Kodak) was
placed in between the screen. The cassette with the hybridized blot and the film
was incubated at -80°C. The next day the cassette was taken out of the -80°C
freezer to thaw and the film was developed with the X-ray film processor.
Characterization of Expressed Chloroplast-Derived Proteins
Extraction of Protein from Transformed Tobacco Leaves
Mature leaf material was harvested around four to five o’clock in the early
evening hours. Leaves were washed in the lab and allowed to air dry and stored
at -80°C until further use. Chloroplast-derived CTB-malarial proteins from
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transgenic lines was extracted by grinding 100 mg of plant tissue with a mortar
and pestle in liquid nitrogen and fine powdered leaf material was placed in a 1.5
mL microcentrifuge tube with a hole poked through the top. The microcentrifuge
tube was immediately placed in liquid nitrogen until further use. 200 µL of plant
extraction buffer (100mM NaCl, 10mM EDTA, 200mM Tris-HCl pH8, 0.05%
Tween 20, 0.1% SDS, 14mM BME, 200mM sucrose, 3.18 mL of sterile H20, and
1 tablet of Roche complete mini EDTA-free protease inhibitor cocktail) was
added to the leaf material. The samples were placed on ice and mixed for two
minutes using a mechanical pestle and centrifuged at 14,000 rpm for fifteen
minutes at 4°C to obtain the supernatant (soluble fraction). The pellet (insoluble
fraction) was resuspended with equal volume of protein extraction buffer and
sonicated for thirty seconds.

The supernatant and pellet was subjected to

Bradford analysis to determine total protein concentration and stored at -20°C
until further use.
SDS-Page and Immunoblot Analysis
Clean Bio-Rad glass plates and casting chamber was set up for SDSPage analysis. 12.5% separating gel (4.15 mL of 30% Acrylamide/Bis solution
(BioRad), 2.5 mL of 4X Separating Buffer: 5M Tris-HCl, pH 8.8, 3.2 mL of H20,
0.1 mL of 10% SDS, 0.1 mL of 10% APS, and 10 µL of TEMED) was mixed in a
50 mL beaker and by using a syringe it was added in between the two glass
plates leaving about 1.5 cm empty for the stacking gel. Immediately water was
added to the top of the separating gel and allowed to polymerize for thirty
minutes. The water was removed with a Kim wipe and 4% stacking gel (665 µL
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of 30% Bio Rad Acrylamide/Bis solution, 1.25 mL of 4X Stacking Buffer: 0.5M
Tris-HCl, pH 6.8, 3.0 mL of H20, 50 µL of 10% SDS, 50 µL of 10% APS, and 5 µL
of TEMED) was prepared. The 4% stacking gel mixture was layered on top of
the resolving gel and a comb was inserted for the formation of wells.

After

polymerization for thirty minutes, the gel was put vertically into the PAGE
apparatus with 1X Protein Buffer (10X Protein Buffer: 0.25M Tris Base, 1.92M
Glycine, and 1% SDS). The protein samples (wild type plants, transgenic plants,
monomeric CTB (Sigma C9903), and E.coli-derived CTB MSP-1) were prepared
by the following: 12 µL of protein extract and 12 µL of 2X gel loading buffer (2.5
mL of 4X Stacking Buffer, 4 mL of 10% SDS, 2 mL of Glycerol, 40 µL of 5%
Bromophenol Blue, 0.31 g of DTT in a total of 10 mL of distilled H20). The
protein samples were boiled for 5 minutes and loaded into the wells along with 7
µL of Precision Plus Protein Standard (BioRad). The gel was run at 85 Volts until
the protein samples entered into the Separating Buffer and the voltage was
increased to 150 Volts until the dye front reached the bottom of the gel. The
proteins from the SDS-PAGE were transferred overnight at 4°C to a HyBond
nitrocellulose membrane via the Bio Rad Transfer Cassette using Transfer Buffer
(200 mL of methanol, 100 mL of 10X Protein Buffer, and 700 mL of H20) and 20
Volts.
For immmunoblot analysis, the membrane was washed three times for five
minutes each with PBS-T and blocked for one hour in 5% PTM at room
temperature. Primary antibody, Anti-Cholera Toxin produced in rabbit (Sigma),
was diluted 1:4,000 in 5% PTM and incubated at room temperature for two
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hours. The membrane was washed three times for ten minutes each with 5%
PTM. Secondary antibody, Stabilized Goat Anti-Rabbit Horseradish PeroxidaseConjugated (PIERCE), was diluted 1:5,000 in 5% PTM and incubated at room
temperature for one hour. Blots were washed with PBS-T two times for ten
minutes each and a final wash of PBS for ten minutes. The membrane was
incubated for five minutes in the dark using SuperSignal West Femto Maximum
Sensitivity Substrate (PIERCE). The membrane was exposed to Classic Blue
Autoradiography Film (MIDSCI) in the dark room and the films were developed
via the film processor to visualize the bands.
Protein Quantification of Expressed Proteins
ELISA was performed to quantify CTB-FC-AMA1 and CTB-MSP-1 in plant
crude extract versus using densitometric analysis because preliminary ELISA
results provided a dilution effect in concentration of protein with increasing
dilutions of the plant extract. Transgenic leaf samples of mature stages along
with wild type were quantified. Total soluble protein was extracted using the
protocol from the section, extraction of protein from transformed tobacco leaves
(p.33-34). CTB (Sigma C9903) was used as the standard and diluted in coating
buffer (1.59 g of Na2CO3, 2.93 g of NaHCO3, and 0.2 g of NaN3 in 1 L of water;
adjusted to pH 9.6 using HCl) ranging from 500-25 pg. Total soluble protein
extracted from wild type non-transgenic plants, CTB-FC-AMA-1 plants, and CTBMSP-1 plants was diluted 1:10, from 1:50,000 – 1:200,000, and from 1:25,000 –
1:150,000 in coating buffer, respectively. A 96 well plate (CoStar EIA/RIA plate,
flat bottom without lid ELISA plate) was coated with 100 µL of CTB standards
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and test samples and incubated overnight at 4°C. The next day, the plate was
washed three times with PBS-T and three times with water.

The plate was

blocked with 300 µL of 3% PTM and incubated for one hour at 37°C. The plate
was washed and 100 µL of primary antibody, Anti-Cholera Toxin produced in
rabbit (Sigma), was diluted 1:4,000 in 3% PTM and incubated for one hour at
37°C.

Following primary antibody, the plate was washed and secondary

antibody, Horseradish Peroxidase-Conjugated Donkey Anti-Rabbit (BioMedia),
was diluted 1:12,500 in 3% PTM and incubated for one hour at 37°C. The plate
was washed and 100 µL of the substrate, TMB (American Qualex Antibodies),
was added and incubated at room temperature for 5 minutes. The reaction was
stopped with 50 µL of 2N sulfuric acid and the plates were read at 450nm with
the BioRad microplate reader, Model 680. A Bradford assay using the Bradford
reagent (Bio-Rad Protein Assay), BSA standards ranging from 0-8 µg/µL,
absorbance of 595 nm, and the SmartSpecPlus Spectrophotometer (BioRad)
was used to determine total soluble protein extracted from the wild type and
transgenic plants.
To determine the quantity of chloroplast-derived CTB-FC-AMA1 and CTBMSP1 the following equation was used. The concentration (pg) derived from the
ELISA multiplied by dilution factor multiplied by 100,000 resulted in concentration
of transgenic protein in µg. The concentration of transgenic protein was then
divided by the volume of sample (100 µL) placed in the well of the ELISA plate.
The number derived after dividing by the volume plated then was divided by the
concentration of total soluble protein (provided by Bradford Analysis) and
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multiplied by 100.

The calculated percentage provides an estimate of the

chloroplast-derived protein accumulation among all proteins expressed by the
plant.
Enrichment of Chloroplast-Derived Proteins
Immobilized Metal Affinity Chromatography
Chloroplast-derived CTB-malarial proteins from transgenic lines was
extracted by grinding 10 g of plant tissue with a mortar and pestle in liquid
nitrogen and fine powdered leaf material was placed in a 50 mL tube with a hole
poked through the top and immediately placed in liquid nitrogen until further use.
20 mL of plant extraction buffer (100mM NaCl, 200mM Tris-HCl pH8, 0.05%
Tween 20, 0.1% SDS, 200mM sucrose, 12 mL of sterile H20, and 1 tablet of
Roche complete mini EDTA-free protease inhibitor cocktail) was added to the
leaf material. The samples were placed on ice and homogenized for five minutes
with an OMNI International (GLH-2596) probe and centrifuged at 14,000 rpm for
fifteen minutes at 4°C to obtain the supernatant (soluble fraction).
The supernatant (lysate) was subjected to TALON Superflow Metal Affinity
Resin (Clontech) to enrich the chloroplast-derived CTB-malarial proteins. The
manufacture’s protocol, BATCH/Gravity-Flow Column Purification, was followed
exactly. The TALON Resin was resuspended thoroughly and 4 mL was placed in
a sterile 50 mL tube and centrifuged at 700 x g for two minutes to pellet the resin.
The pellet was pre-equilibrated twice with ten bed volumes of 1X Wash Buffer
(2.5 mL of 4X Wash Buffer: 0.12M dibasic Na2HPO4, 0.08M monobasic
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NaH2PO4, 1.2M NaCl, 4% Tween-20, made up to 100 mL of sterile H20, pH8;
20mM Imidazole, sterile H20 was added to make up the volume to 10 mL, and 1
tablet of Roche complete mini EDTA-free protease inhibitor cocktail). The plant
extract was added to the resin and agitated at 4°C for two hours. The mixture
was centrifuged at 700 x g for five minutes and the supernatant (flow through)
was removed carefully without disturbing the resin. The mixture was washed
twice with ten bed volumes of 1X Wash Buffer and the supernatant was
discarded. 2 mL of 1X Wash Buffer was added to the resin and transferred to a 2
mL gravity-flow column with an end-cap in place. The end cap was removed and
the buffer was allowed to drain. The column was washed once with five bed
volumes of 1X Wash Buffer.

To elute the chloroplast-derived CTB-malarial

proteins, five bed volumes of Elution Buffer (2.5 mL of 4X Wash Buffer, 20 mM
Imidazole, 100 mM EDTA, volume made up to 10 mL of sterile H20, and 1 tablet
of Roche complete mini EDTA-free protease inhibitor cocktail, pH8) was added
and the elute fraction was collected. The eluted fraction collected along with wild
type material, lysate, flow through, and wash was analyzed with a Bradford and
the Bio-Rad RC-DC Protein Assay to determine protein concentration.

The

eluted fractions were dialyzed with 1X sterile PBS and the Slide-A-Lyzer Dialysis
Cassette 10,000 MW (PIERCE).
Analysis of Chloroplast-Derived CTB-Malarial Protein Enrichment
The eluted, wild type material, lysate, flow through, and wash fractions
were subjected to a gradient gel and immunoblot to determine the efficiency of
enrichment.

7 µg of the CTB FC AMA-1 fractions under reduced and non-
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reduced conditions were heated at 70°C for ten minutes and loaded into a
NuPAGE Novex Bis Tris Gel (Invitrogen) and electrophoresed at 200 Volts until
the dye front reached the bottom of the gel. The gel was rinsed in water and
stained overnight with the GelCode Blue Stain Reagent (PIERCE). 5 µg of the
CTB FC AMA-1 and CTB MSP-1 fractions (eluted, wild type, lysate, flow through,
wash) were electrophoresed and analyzed by an immunoblot.

The primary

antibody, Anti-Cholera Toxin produced in rabbit (Sigma), diluted 1:4,000 in 5%
PTM, was incubated at room temperature for two hours. Secondary antibody,
Stabilized Goat Anti-Rabbit Horseradish Peroxidase-Conjugated (PIERCE),
diluted 1:5,000 in 5% PTM, was incubated at room temperature for one hour.
Following incubation with substrate, membranes were exposed to X-ray film and
developed via the film processor to visualize the bands.
Densitometry
An immunoblot of the eluted chloroplast-derived CTB-malarial proteins
and known quantities of CTB protein was analyzed by using spot densitometric
analysis. 1000, 500, 250, 125 ng of CTB protein (Sigma, C9903) and 1.5, 0.75,
0.375, 0.1875 µg of eluted CTB FC AMA-1 and 1.5, 0.75, 0.375 µg of eluted CTB
MSP-1 was electrophoresed and analyzed by an immunoblot.

The primary

antibody added was rabbit anti-CTB and the secondary antibody was goat antirabbit. Following exposure to film, the blots with known CTB concentrations and
eluted fractions were analyzed by using the AlphaImager and AlphaEase FC
Software (Alpha Innotech).

The concentration of the enriched fraction the

program calculated was divided by the known concentration of the enriched
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fraction loaded and multiplied by one hundred to determine efficiency of the talon
enrichment.
Adsorption of Enriched Protein to Adjuvant
Chloroplast-enriched proteins (~2.5 mg) derived from transgenic tobacco
crude extract was mixed with 1:4 diluted Alhydrogel in PBS (Aluminum Hydroxide
Gel, Sigma) and incubated overnight with gentle rocking at 4°C. The samples
were centrifuged at 2,000 x g for five minutes at 4°C. The RC-DC Protein Assay
(BioRad) was used to determine the adsorption efficiency by comparing the total
amount of protein added to the adjuvant and the protein remaining in the
supernatant after binding to adjuvant.

The protein-adsorbed pellet was

resuspended in sterile PBS to a final concentration of 1 µg/µL.
Immunizations
For subcutaneous injections 100 µL of Alhydrogel or chloroplast-derived
protein adsorbed to Alhydrogel was injected into the scruff of the neck using a
tuberculin syringe fitted with a 27-G needle. The leaf material for the doses for
oral delivery was previously ground in liquid nitrogen with mortars and pestles
and stored at -80°C until the day of immunization. Oral doses (500 mg each) of
either wild type or transgenic leaf material was resuspended in 200 µL of sterile
PBS and homogenized on ice for five minutes with an OMNI International (GLH2596) probe. The plant cell suspension was stored on ice until oral delivery. 200
µL of the plant cell suspension was delivered via oral gavage by using a
tuberculin syringe and a 20-G bulb-tipped gastric gavage needle.
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Ninety female BALB/c mice were purchased at 7 weeks from Charles
River Laboratories and were immunized by the following schedule listed below.
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Table 1: Schedule of Immunization of Mice

Group

Immunization
Type

Immunization Sample

Route of
Administration

Schedule

Amount of
Material or
Antigen
Delivered
Per Dose

Boost

WT PH

Oral

0 µg

Boost

AlH

s.c.

Days 10, 17, 24,
31, 37, 45, 52,
59, 150, 157, 189
Days 13, 27, 43,
55, 150, 189

Prime
Boost

enCTB FC AMA-1
enCTB FC AMA-1

s.c.
s.c.

Day 0
Days 13, 27, 43,
55, 150, 189

25 µg
25 µg

Prime
Boost

enCTB FC AMA-1
CTB FC AMA-1

s.c.
Oral

25 µg
500 mg***

Prime
Boost

enCTB MSP-1
enCTB MSP-1

s.c.
s.c.

Day 0
Days 10, 17, 24,
31, 37, 45, 52,
59, 150, 157,
189, 220
Day 0
Days 13, 27, 43,
55, 150, 189

Prime
Boost

enCTB MSP-1
CTB MSP-1

s.c.
Oral

25 µg
500 mg***

Prime

enCTB FC AMA-1
enCTB MSP-1
enCTB FC AMA-1
enCTB MSP-1
enCTB FC AMA-1
enCTB MSP-1
CTB FC AMA-1
CTB MSP-1

s.c.

Day 0
Days 10, 17, 24,
31, 37, 45, 52,
59, 150, 157, 189
Day 0
Days 13, 27, 43,
55, 150, 189
Day 0

25 µg

1
2
3
4
5
6
7

Boost
Prime

8

Boost

9

Nothing

s.c.
s.c.
Oral

Nothing

Nothing

Days 10, 17, 24,
31, 37, 45, 52,
59, 150, 157, 189
Nothing

10 Mice Per Group: 90 mice Total
WT PH: Non-transgenic tobacco plants
AlH: Alhydrogel (Adjuvant)
Oral: Oral gavage
s.c: Subcutaneous injection
enCTB FC AMA-1: Enriched CTB FC AMA-1
CTB FC AMA-1: Transgenic tobacco plants expressing CTB FC AMA-1
enCTB MSP-1: Enriched CTB MSP-1
CTB MSP-1: Transgenic tobacco plants expressing CTB MSP-1
***ORAL DELIVERY: Leaf material not antigen
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0 µg

25 µg
25 µg

25 µg

25 µg
500 mg***

0 µg

Determination of Antibody Titers from Serum Samples
Blood Samples Collection
Blood samples were obtained on days 21, 35, 63, 163, and 197-post
immunization. The mouse was restrained and blood was collected by inserting a
golden rod animal lancet 4mm, 5mm, or 5.5mm, depending on the age and size
of the mouse, in the submandibular vein. The blood was collected in Microtainer
serum separation tubes (Becton-Dickinson) and allowed to clot for a minimum of
30 minutes at room temperature. The blood samples were centrifuged at 15,000
rpm for 5 minutes and the serum was transferred to new microcentrifuge tubes
and stored at -80°C.
ELISA to Determine Antibody Titers
96 well plates (CoStar EIA/RIA plate, flat bottom without lid ELISA plate)
were coated with 100 ng of CTB (Sigma C9903) or 50 ng of MRA-49 PfMSP119
protein in coating buffer (1.59 g of Na2CO3, 2.93 g of NaHCO3, and 0.2 g of NaN3
in 1 L of water; adjusted to pH 9.6 using HCl) per well.

The plates were

incubated overnight at 4°C. The following day, the plates were washed three
times with PBS-T and water and blocked with PBS containing 0.1% Tween and
3% skim milk powder for one hour at 37°C.

The following dilutions were

prepared in PTM to determine CTB titers for all control and experimental mice:
bleed #1 ranging from 1:1,000 to 1:50,000; bleed #2 ranging from 1:25,000 to
1:150,000; bleed #3 ranging from 1:50,000 to 1:400,000; and bleeds #4 and #5
ranging from 1:100,000 to 1:800,000.

For quantification of MSP-1 titers, the
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serum samples from groups 5, 6, and 9 (unimmunized) were diluted in PTM with
the following dilutions: bleed #1 and #2 ranging from 1:100 to 1:1000; bleed #3
from 1:250 to 1:25,000; bleed #4 from 1:500 to 1:25,000; and bleed #5 from
1:1000 to 1:50,000.

The plates were washed and incubated with 100 µL of

diluted serum samples (in duplicate) and incubated for one hour at 37°C. The
plates were washed and incubated with 100 µL of 1:5,000 diluted goat anti
mouse IgG1 (American Qualex) conjugated with horseradish peroxidase enzyme
in PTM for one hour at 37°C. The plates were washed and 100 µL of TMB
substrate (American Qualex Antibodies) was added and incubated at 37°C for
thirty minutes. The reaction was stopped with 50 µL of 2N sulfuric acid and the
plates were read at 450nm with the plate reader (BioRad microplate reader,
Model 680). The titer values were determined by using the O.D. (optical density)
of the negative control (unimmunized mice, group 9) + 0.1.
Immunoblot for Detection of Anti-Malarial Antibodies from Serum Samples
The immunoblot protocol followed was mentioned above in the
characterization of chloroplast-derived proteins (p.34-35). The protein samples
loaded into the SDS-PAGE gel were isolated prior and stored in the -80° freezer.
36.8 µg of ring, trophozoite, and schizont stage proteins were electrophoresed
and analyzed by an immunoblot. The primary antibody, sera collected from an
immunized mouse from groups 3 and 5, used was diluted 1:100 in 5% PTM.
Secondary antibody, Stabilized Goat Anti-Mouse Horseradish PeroxidaseConjugated (PIERCE), was diluted 1:5,000 in 5% PTM. Following incubation

38

with substrate, membranes were exposed to X-ray film and developed via the
film processor to visualize the bands.
IFA for Detection of Anti-Malarial Antibodies from Serum Samples
A revised protocol by Tonkin et al. was followed for the preparation and
fixation of cells (Tonkin, van Dooren et al. 2004) for IFA analysis. Cells were
washed once with PBS and fixed in 4% paraformaldehyde and 0.0075%
glutaraldehyde in PBS for 30 min at room temperature. Following fixation, cells
were washed once with PBS and permeabilized with 0.1% Triton X-100 (Sigma)
for ten minutes and to reduce free aldehydes cells were treated with 0.1 mg/mL
NaBH4/PBS for ten minutes at room temperature. Cells were washed once with
PBS and finally blocked with 3% BSA/PBS for one hour at room temperature.
Cells were probed with antibodies, (sera obtained from a immunized mouse in
group 3 and 5) diluted 1:500 in 3% BSA/PBS for two hours at room temperature
followed by three washes with PBS. The secondary antibodies were Alexa Fluor
555 goat anti-mouse diluted 1:1000 in 3% PBS containing BSA and inverted in
the dark for one hour at room temperature. Cells were washed three times with
PBS and allowed to settle on previously coated coverslips with 1% PEI for thirty
minutes at room temperature.

The mounting solution, 50% glycerol with

0.1 mg/mL DABCO (Sigma) was added to the coverslips and then inverted on
microscope slides. Fluorescence images were observed and captured by using
an LSM 510 confocal laser scanning microscope (Carl Zeiss).
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In Vitro Parasite Inhibition Assay
The 3D7 P. falciparum culture was synchronized with ring stage parasites
and sorbitol lysis. The parasite completed one cycle and was allowed to mature
to the trophozoite-schizont stage. The hematocrit and parasitemia were adjusted
to 2% (2.5% parasitemia for the MRA-35 PfMSP119 in vitro parasite inhibition
assay).

Mouse sera and MRA-35 PfMSP119 (positive control) were heat

inactivated at 56°C for 30 minutes and absorbed with human RBCs overnight at
4°C (Sachdeva, Mohmmed et al. 2006). The mouse serum was added to the
parasite culture in 96 well plates at a final concentration of 20% (for the MRA-35
PfMSP119 in vitro parasite inhibition assay 5 µL of antibody was added and
diluted 1:5 – 1:625 to 25 µL of parasite culture). To serve as a negative control,
no serum was added to wells and replaced with culture media. The cultures
were incubated for 48 hours to allow for schizont rupture and merozoite invasion.
These assays were preformed in duplicate. For microscopic analysis using the
100X oil immersion lens, blood smears were made and stained with Giemsa and
the numbers of parasites per 900-1,100 RBCs were determined for each well.
Parasitemia was measured using the following formula (infected RBCs /
infected+uninfected RBCs) x 100. Percent of inhibition was determined by the
following formula (% parasitemia of no sera added - % parasitemia of
experimental mouse sera / % parasitemia of no sera added) x 100. Relative
percent of inhibition was determined by the following formula (% of inhibition from
experimental mouse sera / % inhibition of MRA-35 PfMSP119 (positive control)) x
100 and the percent of inhibition for the positive control was set at 100%.
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Pictures were taken from the slides to show the extent of parasitemia and
inhibition under the light microscope.
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RESULTS
Amplification of AMA-1 and MSP-1 in Asexual Stages and CTB
To verify AMA1 and MSP-1 expression in 3D7 P. falciparum parasites,
transcripts were detected by RT-PCR by using total RNA from mixed stages of
parasites and gene-specific primers (Figure 2). By using gene-specific primers,
CTB template DNA, and PCR; CTB was amplified with the expected size as
shown in Figure 2.

Figure 2: PCR and RT-PCR Analysis of CTB, FC AMA-1, and MSP-1
DNA was amplified using a single tube PCR and RT-PCR approach and gene
specific primers as discussed under “Materials and Methods” resulting in Lane 2:
(CTB, 332 bp), Lane 4: (FC AMA-1, 383 bp), and Lane 6: (MSP-1, 289 bp).
Molecular size standards are indicated in Lanes 1, 5: 1 kb + ladder and Lane 3: 1
kb ladder.
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Cloning Analysis into Chloroplast Vector
The inserts, FC AMA-1, MSP-1, and CTB, were successfully cloned into
the pGMET easy and pBSK+ vectors successfully (data not shown). The DNA
sequences were confirmed after successful ligation into the pGEMT easy vector.
Once the transgene fusions, CTB FC AMA-1 and CTB MSP-1, were constructed
in the pBSK+ vector, the constructs were excised and ligated into the chloroplast
pLD-UTR vector with expected sizes as shown in Figure 3. The constructs were
then bombarded into the tobacco plant Nicotiana tabacum variety Petit Havana
by the protocol listed in the “Materials and Methods” section.

Figure 3: Analysis of Cloning CTB FC AMA-1 and CTB MSP-1 Into the pLD-UTR
Chloroplast Vector
After purifying plasmid DNA with the Qiagen Plasmid Maxi Kit, the DNA was
analyzed by gel electrophoresis.

CTB FC AMA-1 is depicted in Lane 3:
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undigested and Lane 6: digested with NotI and NdeI resulting in a 715 bp
fragment. CTB MSP-1 is illustrated in Lane 7: after digestion with NotI and NdeI
(621 bp fragment). In Lanes 2, 4, 5: genes were inserted into the pLD-UTR
vector but were not further studied.

Molecular size standards are indicated in

Lanes 1, 8: 1 kb ladder.
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Confirmation of Chloroplast Integration of Transgenes
The gene cassette (aadA and CTB FC AMA-1/CTB MSP-1) was
introduced

into

the

tobacco

chloroplast

genome

through

homologous

recombination of the flanking sequences of the pLD-UTR vector (trnI and trnA)
and the native plastid genome. The Prrn downstream of the trnI gene is for
transcription of aada that confers resistance to spectinomycin and streptomycin
and the transgene that encodes the CTB-malarial gene. The 3' UTR upstream of
the trnA gene provides stability for the transcript and may be involved in
ribosome recruitment.
Five to six resistant shoots appeared on the regeneration media (RMOP)
containing spectinomycin. Using specific primers and PCR analysis, mutant and
nuclear integrated shoots were differentiated from shoots where the transgene
integrated into the chloroplast genome. By using 3P/3M primers, site-specific
integration of the gene cassette was confirmed.

To eliminate all nuclear

transformants, the 3P primer was used because it annealed to the native
chloroplast genome. The 3M primer was used because it landed on the aadA
gene and eliminated all mutant transformants.

The 3P/3M primers, resistant

shoots, and PCR analysis yielded a 1.65 kb band as shown in Figure 4 (left
panels). Another set of primers 5P/2M were used to confirm the integration of
the aadA gene and the CTB-malarial gene. The 5P primer annealed to the aadA
gene and the 2M primer annealed to the trnA gene. The amplified PCR product
size was 2.3 kb for CTB FC AMA-1 and 2.2 kb for CTB MSP-1 as shown in
Figure 4 (right panels). The 5P/2M PCR analysis eliminated all mutants and
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only positive transformants with transgene integration were visualized. The
positive transformants were subjected to second and third round of selection to
advance towards homoplasmy.

Figure 4: PCR Analysis of Wild Type and Positive Transformants
PCR using specific primers land within the native chloroplast genome and the
aadA gene (3P3M) to yield a 1.65 kb product Lanes 2, 14: positive control,
Lanes 3, 15: wild type, Lanes 4-6: transgenic lines pLD-UTR CTB FC AMA-1,
and Lanes 16, 17: transgenic lines pLD-UTR CTB-MSP-1. Using the specific
5P/2M primers, landing on the aadA gene and trnA gene, respectively yields a
2.3 kb and 2.2 kb product Lanes 8, 19: positive control, Lanes 9, 20: wild type,
Lanes 10, 11: negative transformants pLD-UTR CTB FC AMA-1, Lane 12:
transgenic line pLD-UTR CTB FC AMA-1, and Lanes 21, 22: transgenic lines
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pLD-UTR CTB-MSP-1. Molecular size standards are indicated in Lanes 1, 7, 13,
18: 1 kb + ladder.
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Southern Analysis of Transgenic Plants
To

confirm

site-specific

integration

and

homoplasmic

plants,

untransformed and transgenic plant genomic DNA was probed with the 2P/2M
flanking sequence probe of 1.3 kb in size. The transgenic and non-transgenic
genomic DNA was digested with the restriction enzyme ApaI. After digestion, the
untransformed chloroplast genome resulted in a 4.5 kb fragment and the
transformed chloroplast genome resulted in 6.5 and 6.6 kb fragments for CTB
MSP-1 and CTB FC AMA-1, respectively, as depicted in Figure 5. The absence
of the 4.5 kb fragment in the transplastomic lines confirms homoplasmy (Figure
5).
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Figure 5: Evaluation of Transgene Integration into the Chloroplast Genome of
Homoplasmic Plants by Southern Blot
Southern blot probed with the 2P/2M flanking sequence probe to determine
homoplasmy Lane 1: wild type, Lane 2: homoplasmic CTB MSP-1 (6.5 kb), and
Lane 3: homoplasmic CTB FC AMA-1 (6.6 kb).
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Selection and Generation of Transgenic Plants
Transgenic plants were selected and generated by the use of RMOP
media and spectinomycin (Figure 6A).

After positive transformants were

determined by PCR analysis, further selection and generation of transgenic
shoots was maintained (Figure 6B).

MSO selection media containing

spectinomycin was used for rooting. Once the in vitro plants were confirmed
homoplasmic by Southern Blot analysis the plants were transferred to the
greenhouse for optimal growth and maximal protein expression (Figure 6C). No
pleiotropic effects were observed with the transgenic plants (CTB FC AMA-1,
middle plant and CTB MSP-1, right plant) in comparison with untransformed
control (left plant) (Figure 6C).

50

Figure 6: Generation of Transgenic Plants
(A) Four to five weeks after particle bombardment, transplastomic shoots appear
on RMOP selection medium. For second round of selection, leaves from PCR
positive transformants are transferred to RMOP selection medium. (B) Several
shoots appear within two to three weeks.

For third round of selection,

regenerated shoots are transferred to MSO selection medium and roots appear
in about 10 days.

(C) Plants were transferred to the greenhouse after

confirmation of homoplasmic plants via Southern blot analysis. In the picture,
from left to right the following plants are visualized: untransformed control, CTB
FC AMA-1, and CTB MSP-1.
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Characterization of the Chloroplast-Derived CTB Malarial Proteins
Crude extracts of approximately 50 µg of wild type and transgenic plants
along with monomeric CTB protein and an E.coli expressed CTB MSP-1 extract
were loaded in the wells of a SDS-PAGE gel. The blots were probed with the
polyclonal anti-CTB primary antibody and the monomeric forms of CTB FC AMA1 showed a 27.5 kDa protein and CTB MSP-1 depicted a 23 kDa protein in the
insoluble (pellet) and soluble (supernatant) fractions (Figure 7). The immunoblot
displayed others forms of the CTB-malaria proteins such dimers, trimers,
tetramers, and pentamers (Figure 7).

Figure 7: Immunoblot Analysis to Confirm Expression of CTB-Malarial Antigens
in Nicotiana tabacum Crude Extracts
Immunoblot with anti-CTB polyclonal antibody showed full-length protein. Lanes
1, 5: negative control wild type extract, Lane 2: positive control monomeric 11.6
kDa CTB protein, Lane 6: positive control CTB MSP-1 E. coli expressed protein,
Lane 3: CTB FC AMA-1 pellet, Lane 4: CTB FC AMA-1 supernatant, Lane 7:
CTB MSP-1 pellet, and Lane 8: CTB MSP-1 supernatant.

52

Quantification of Chloroplast-Derived CTB Malarial Proteins
To determine the concentration of the chloroplast derived CTB-malarial
proteins, a standard ELISA was performed.

Using CTB protein of known

concentrations, a standard curve was generated as depicted in Figure 8 (top
panel). The ELISA displayed a dilution effect with the diluted crude plant extracts
and the standard curve (data not shown). The CTB FC AMA-1 and CTB MSP-1
protein expression levels of mature leaves reached 6.3-9.5% and 1.4-2%,
respectively as shown in Figure 8 (bottom panel). The accumulation of the CTBmalarial proteins in high level of expression is due to the presence of high
number of chloroplasts and chloroplast genomes (up to 10,000 copies per cell).
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Figure 8: Quantification of Chloroplast-Derived CTB-Malarial Expression
An ELISA with the following expression levels determined quantification: 6.39.5% of CTB FC AMA-1 and 1.4-2% of CTB MSP-1 of total soluble protein of
mature leaves.
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Enrichment of Chloroplast-Derived CTB-Malarial Proteins
Resolution of Enriched Proteins
A crude extract of chloroplast-derived proteins was subjected to
immobilized metal affinity chromatography by using the TALON Superflow Metal
Affinity Resin and analysis followed. A NuPAGE Novex Bis-Tris gradient gel was
used to increase the resolution of the enriched CTB FC AMA-1 protein. The gel
was performed under reduced and non-reduced conditions. The large subunit of
rubisco (55 kDa) is apparent in the wild type, lysate, and flow through fractions
under reduced and non-reduced conditions (Figure 9). In the wash fractions
there are minimal bands present. In the eluted CTB FC AMA-1 fraction, the
monomer of 27.5 kDa in size is present under reduced conditions (Lane 6) and
the pentameric form is present under both reduced (Lane 6) and non-reduced
(Lane 13) conditions (Figure 9).
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Figure 9: Increased Resolution of Chloroplast-Derived CTB FC AMA-1 Protein
After Immobilized Metal Affinity Chromatography
CTB FC AMA-1 protein was extracted from transformed leaves and the crude
extract was subjected to Talon Superflow Metal Affinity Resin and analyzed.
Lanes 2-6: reduced and Lanes 8-12: non-reduced conditions of CTB FC AMA-1
protein enrichment was observed by using a gradient gel (4-12%) and gel
electrophoresis. The following fragments were visualized Lanes 2, 8: wild type,
Lanes 3, 9: lysate, Lanes 4, 10: flow through, Lanes 5, 11: wash, and Lanes 6,
12: enriched protein. Molecular size standards are indicated in Lanes 1, 7: 1 kb
ladder.
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Immunoblot Analysis of Enriched Proteins
An immunoblot probed with anti-CTB antibody was conducted to confirm
the presence of the CTB-malarial proteins after talon enrichment. Equal amounts
of protein from wild type, lysate, flow through, wash, and enrichment was loaded
into the gel and visualized via an immunoblot. In the fractions containing protein
harvested from wild type leaves resulted in no apparent band in the immunoblot
analysis (Figure 10). Lower levels of CTB-malarial proteins were found in the
flow through and wash fractions compared to the lysate and in the enriched
fractions significant protein expression were found confirming enrichment of the
CTB-malarial proteins (Figure 10).

Figure 10: Immunoblot Analysis of Enrichment of Malarial Antigens from
Nicotiana tabacum Extracts
Malaria protein was extracted from transformed leaves and the crude extract was
subjected to Talon Superflow Metal Affinity Resin and the following fractions
were collected and analyzed using an immunoblot with polyclonal anti-CTB

57

antibody: Lanes 1, 6: wild type, Lanes 2, 7: lysate, Lanes 3, 8: flow through,
Lanes 4, 9: wash, and Lanes 5, 10: eluted CTB FC AMA-1 and CTB MSP-1,
respectively.
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Densitometric Analysis
An immunoblot with known concentrations of CTB protein and different
concentrations of the enriched fractions were probed with anti-CTB antibody.
Quantification of the enriched CTB-malarial proteins on immunoblots was
analyzed by spot densitometry. Linearity of the standard curve was achieved by
using 1000, 500, 250, and 125 ng of CTB (data not shown) and assisted in the
estimation of the enriched samples in the same blot (Figure 11). The standard
curve provided the concentration of the enriched fractions and the efficiency of
the talon enrichment was determined to be 90% and 73% in CTB FC AMA-1 and
CTB MSP-1, respectively.

Figure 11: Immunoblot of the Eluted Protein Fractions were Analyzed and
Compared to Known Quantities of CTB Protein
Immunoblot analysis of Lanes 1-4 and 10-13: CTB protein (1000, 500, 250, 125
ng, respectively), Lanes 6-9: eluted CTB FC AMA-1 (1.5, 0.75, 0.375, 0.1875 µg,
respectively), and Lanes 14-16: eluted CTB MSP-1 (1.5, 0.75, 0.375 µg,
respectively).

Eluted proteins and CTB were subjected to densitometry to
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determine the enrichment of CTB FC AMA-1 and CTB MSP-1 to be administered
to mice for subcutaneous injection.
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Immunogenicity of the Chloroplast-Derived CTB Malarial Antigens
Quantitation of CTB Titers from Immunized Mice
The serum collected from the five bleeds following immunization were on
days 21, 35, 63, 163, and 197-post immunization. The serum was tested for antiCTB antibodies by a capture ELISA with CTB protein. Minimal mice titers were
detected from bleeds #1 and #2 ranging from 1:1,000 – 1:150,000 and titers were
present ranging from 1:50,000 – 1:800,000 in bleeds #3, #4, and #5 (Figure 12).
Titers for anti-CTB were found to be higher in groups 3, 5, 6, 7, and 8 versus
group 4 (oral delivery CTB FC AMA-1) (Figure 12). No CTB titers were found for
group 1 (oral delivery non-transgenic leaf material) or group 2 (subcutaneous
injection alhydrogel alone).

Figure 12: Immunogenicity of CTB Titers Using a Capture ELISA
ELISA detection of anti-CTB antibody titers from groups 1 – 8 serum samples
collected from five bleeds.
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Quantitation of MSP-119 Titers from Groups 5 and 6
The serum collected from the five bleeds following immunization was
tested for anti-PfMSP119 antibodies by a capture ELISA with MRA-49 PfMSP119.
Minimal mice titers were detected from bleeds #1 and #2 and titers were present
ranging from 1:100 – 1:50,000 in bleeds #3, #4, and #5 (Table 2). Titers for antiPfMSP119 were found to be higher in group 5 (subcutaneous injection) than in
group 6 (oral delivery) (Table 2). Four mice in groups 5 and 6 (5A1, 5B3, 6A1,
6B4) showed undetectable titers with MRA-49 PfMSP119 protein (Table 2) but
showed similar CTB titers with the other mice in the group.
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Table 2: Immunogenicity of a Malarial Antigen Using MSP-1 Protein
Mouse #

MSP-1 IgG1
MSP-1 IgG1
MSP-1 IgG1
MSP-1 IgG1
MSP-1 IgG1
Titers Bleed #1 Titers Bleed #2 Titers Bleed #3 Titers Bleed #4 Titers Bleed #5

5A1

0

0

0

0

0

5A2

100

1000

25000

25000

50000

5A3
5A4

1000

1000

25000

25000

25000

100

1000

12500

25000

50000

5A5

0

1000

1000

1000

1000

5B1

0

0

250

1000

12500

5B2

100

1000

12500

25000

25000

5B3

0

0

0

0

0

5B4

0

1000

25000

25000

50000

5B5

0

0

1000

1000

12500

6A1

0

0

0

0

0

6A2

0

500

1000

12500

12500

6A3

100

250

1000

12500

12500

6A4

100

1000

1000

1000

1000

6A5

0

0

250

1000

1000

6B1
6B2

0

0

250

1000

1000

500

1000

12500

12500

12500

6B3

0

100

1000

1000

1000

6B4

0

0

0

0

0

6B5

0

250

1000

12500

12500

ELISA detection of anti-MSP-1 antibody titers from groups 5 and 6 serum
samples collected from five bleeds.
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Recognition of Parasite Protein by Anti-Malarial Antibodies
An immunoblot confirmed anti-malarial antibodies from immunized mice
recognized parasite protein from P. falciparum infected erythrocytes. Anti-AMA-1
antibodies, sera collected from a mouse immunized with CTB FC AMA-1 antigen,
recognized the ring and schizont stages with the presence of an 83 kDa band
(Figure 13). The serum from an immunized mouse from group 5 contained antiMSP-1 antibodies, which recognized ring and schizont stages with an apparent
190 kDa band (Figure 13).

Figure 13: Recognition of Parasite Protein by Anti-AMA-1 and Anti-MSP-1
Antibodies
36.8 µg of ring, trophozoite, and schizont parasite protein was loaded into the
SDS PAGE gel and analyzed by an immunoblot with 1:1,000 diluted sera from
immunized mice. Immunoblot displaying Lanes 1-3: anti-AMA-1 collected from
an immunized mouse recognizes 83 kDa AMA-1 protein and Lanes 4-6: antiMSP-1 recognizes 190 kDa MSP-1 protein. The parasite stages analyzed from
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the 3D7 P. falciparum culture include Lanes 1, 4: ring, Lanes 2, 5: trophozoite,
and Lanes 3, 6: schizont.
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Recognition of Parasite by Anti-Malarial Antibodies
Sera collected from immunized mice with chloroplast-derived CTB-malarial
antigens resulted in the recognition of parasite localization.

Anti-AMA-1

antibodies were found in the immunized sera because parasites were stained in
the apical end of the ring stage parasite (Figure 14 B, C). A mouse immunized
with the chloroplast-derived CTB-MSP-1 antigen resulted in stained schizonts
indicating the presence of anti-MSP-1 antibodies (Figure 14 E, F).

Figure 14: Recognition of Parasite by Anti-AMA-1 and Anti-MSP-1 Antibodies
Visible and immunofluorescence (IFA) images of 3D7 P. falciparum parasite
immunostained with (A, B, C) anti-AMA-1 raised in mice displaying recognition of
the apical end of the parasite and (D, E, F) anti-MSP-1 collected from immunized
mouse sera recognizing the MSP-1 of a schizont parasite.
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In Vitro Parasite Inhibition Assay
Anti-AMA-1 and Anti-MSP-1 Antibodies Prevent Invasion
An in vitro parasite inhibition assay was performed to test the ability of
anti-AMA-1 and anti-MSP-1 antibodies in inhibiting parasite entry into
erythrocytes.

Synchronized

trophozoite-schizont

stage

parasites

(2%

parasitemia and hematocrit, Figure 15 A) were incubated with control and test
sera for forty-eight hours and blood smears were made. The slides were stained
with Giemsa and the number of parasites and total number of RBCs were
counted.

The parasitemia was determined and the percent inhibition was

calculated. The predominant stage found under microscopic examination was
the ring stage. The average parasitemia for the blank control (no serum added)
was determined to be 6.6% (Figure 15 B) while the lowest parasitemia found
was from group 5, subcutaneous CTB MSP-1 (2.5%, Table 3) and in mouse 5A4
with the highest MSP-119 titer of 50,000 (2.4%, Figure 15 C) representing the
group and the mouse with highest percent of relative inhibition to the positive
control (117.2%, Table 3) and percent of inhibition (63.6%, Table 4),
respectively, of parasite invasion. The remaining experimental groups displayed
85.8 – 105.8% relative inhibition to the positive control (Table 3). The control
groups who did not receive chloroplast-derived CTB-malarial antigen resulted in
14.3 – 25.7% relative inhibition to the positive control (Table 3). The immunized
mouse, 6B3, with the lowest MSP-119 titer of 1,000 was found to exhibit the
highest parasitemia (3.5%, Figure 15 D) after the in vitro parasite inhibition
assay. The serum from the positive control (MRA-35 rabbit antiserum against
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purified recombinant yeast secreted PfMSP1-19, 3D7) resulted in only 53%
inhibition (Table 4). The control groups (groups 1, 2, 9) resulted in 7.6 – 13.6%
inhibition and mice 5B5 and 6B5 with a MSP-119 titer of 12,500 resulted in 59.1%
and 54.5%, respectively (Table 4).

Table 3: Calculation of Average Parasitemia and Relative Inhibition of
Experimental Mice Sera After an in Vitro Parasite Inhibition Assay

Group

Parasitemia

Mean Parasitemia Relative Inhibition

No Ab

6.6 - 6.7%

6.6%

-

MRA-35 PfMSP1-19

2.5 - 3.5%

3.1%

100.0%

Group 1

5.9 - 6.6%

6.1%

14.3%

Group 2

5.5 - 6.2%

5.8%

22.8%

Group 3

2.8 - 3%

2.9%

105.8%

Group 4

2.4 - 3.3%

3.0%

102.8%

Group 5

2.4 - 2.6%

2.5%

117.2%

Group 6

2.6 - 3.6%

3.2%

97.2%

Group 7

2.7 - 3.9%

3.3%

94.3%

Group 8

3.3 - 3.8%

3.6%

85.8%

Group 9

5.6 - 5.8%

5.7%

25.7%

Synchronized 3D7 P. falciparum trophozoite-schizont stage culture (2%
parasitemia and hematocrit) and no sera, MRA-35 PfMSP1-19 sera, and
immunized mouse sera was incubated for 48 hours; the parasitemia was
estimated and relative percent of inhibition was determined in comparison to the
positive control.
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Table 4: Calculation of Average Parasitemia and Percent Inhibition of Selected
Mice After an in Vitro Parasite Inhibition Assay

Group

MSP-1

19

Titer

Parasitemia

Inhibition

No Ab (Control)

–

6.6%

–

MRA-35 PfMSP1-19

–

3.1%

53%

Group 1

0

6.1%

7.6%

Group 2

0

5.8%

12.1%

Mouse 5A4 (s.c.)

50000

2.4%

63.6%

Mouse 5B5 (s.c.)

12500

2.7%

59.1%

Mouse 6B3 (oral)

1000

3.5%

47%

Mouse 6B5 (oral)

12500

3.0%

54.5%

Group 9

0

5.7%

13.6%

Synchronized 3D7 P. falciparum trophozoite-schizont stage culture (2%
parasitemia and hematocrit) and no sera, MRA-35 PfMSP1-19 sera, and
immunized mouse sera was incubated for 48 hours; the parasitemia was
estimated and percent of inhibition was determined.
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Figure 15: Microscopic Examination of the in Vitro Parasite Inhibition Assay
Synchronized 3D7 P. falciparum trophozoite-schizont stage culture 2%
parasitemia and hematocrit (A), and no sera (B), sera from mouse 5A4 (C), and
sera from mouse 6B3 (D) was incubated for 48 hours; the parasitemia was
estimated by counting infected and uninfected RBCs.
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Anti-MRA-35 PfMSP1-19 Antibodies Prevent Invasion
An in vitro parasite inhibition assay was performed to test the ability of
anti-MRA-35 PfMSP1-19 antibodies inhibiting parasite entry into erythrocytes in a
dose-dependent manner.

Synchronized trophozoite-schizont stage parasites

(2.5% parasitemia and 2% hematocrit, Figure 16 A) were incubated with 5 µL
and diluted 1:5-1:625 MRA-35 PfMSP1-19 antibodies for forty-eight hours and
blood smears were made. The slides were stained with Giemsa and the number
of parasites and total number of RBCs were counted.

The parasitemia was

determined and the percent inhibition was calculated. The predominant stage
found under microscopic examination was the ring stage.

The average

parasitemia for the blank control (no serum added) was determined to be 8.0%
(Table 5, Figure 16 B) while parasitemia ranged from 3-5.5% and the percent of
inhibition ranged from 62.5-31.3% from least to most diluted sera, respectively
(Table 5, Figure C, D).
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Table 5: Calculation of Average Parasitemia and Percent Inhibition After in Vitro
Parasite Inhibition Assay Using Different Dilutions of MRA-35 PfMSP-1-19
Antibody
Group

Parasitemia

Average

Inhibition

Parasitemia
Blank (Control)

6.9-8.9%

8.0%

–

5 µL

2.7-3.3%

3.0%

62.5%

1:5 Dilution

3.4-3.8%

3.6%

55%

1:25 Dilution

4-4.4%

4.2%

47.5%

1:125 Dilution

4.3-5.1%

4.8%

40.0%

1:625 Dilution

5.4-5.7%

5.5%

31.3%

Synchronized 3D7 P. falciparum trophozoite-schizont stage culture (2.5%
parasitemia and 2% hematocrit); no sera or MRA-35 PfMSP1-19 sera was
incubated for 48 hours; the parasitemia was estimated and percent of inhibition
was determined.
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Figure 16: Microscopic Examination of the in Vitro Parasite Inhibition Assay After
Adding Different Dilutions of MRA-35 PfMSP-1-19 Antibody
Synchronized 3D7 P. falciparum trophozoite-schizont stage culture 2.5%
parasitemia and 2% hematocrit (A), and no sera (B), 5 µL of MRA-35 PfMSP1-19
antibody (C), and 1:625 diluted MRA-35 PfMSP1-19 antibody (D) was incubated
for 48 hours; the parasitemia was estimated by counting infected and uninfected
RBCs.
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DISCUSSIONS
Currently, there is no licensed vaccine for the prevention of malarial
disease despite the vast knowledge of genomics and proteomics of the malaria
parasite (Sharma and Pathak 2008).

The need for a malarial vaccine is

imperative because the global burden of the disease is increasing due to drug
resistance, mosquito’s resistance to insecticides, ineffective control measures,
re-emergence of the disease, and increased tourism. Malaria vaccine research
has investigated several vaccine candidates in clinical trials but with
disappointing results in low titers and poor efficacy. Previous studies have lead
to the discovery of AMA-1 and MSP-1, which are two of the leading asexual
blood-stage malarial vaccine candidates. The malarial genes, AMA-1 and MSP1, were successfully amplified via PCR along with the transmucosal carrier, CTB.
CTB was included in the present study because of it’s potential adjuvant activity
on the immune system and possibility of performing as an oral immunogen (Li
and Fox 1996). The fusion CTB-malarial gene cassettes were constructed in the
pBSK+ vector.
Malaria antigens have been expressed in several expression systems
such as in E. coli (Sachdeva, Mohmmed et al. 2006), yeast (Gozalo, Lucas et al.
1998), and mammalian cells (Burghaus, Gerold et al. 1999) but plants could be
considered as an alternative in vaccine development because they can reduce
cost due to the expense of fermentation, purification, processing, cold storage,
and delivery.

The purpose of expressing the CTB-malarial antigens in the

chloroplast system was to develop a safer and more effective malarial vaccine.
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By using the flanking sequences trnI and trnA, the chloroplast pLD-UTR vector
with the CTB-malarial cassette was integrated into the chloroplast genome via
homologous recombination. The pLD-UTR vector contains the aadA gene, which
codes for the enzyme aminoglycoside 3’ adenyltransferase and transgenic
shoots were allowed to overcome the selection of spectinomycin (Svab and
Maliga 1993; Verma and Daniell 2007). 3P/3M and 5P/2M primers along with
PCR confirmed the integration of the gene cassette into the chloroplast genome.
The positive transformants were subjected to second and third round of selection
to remove any remaining wild type cells. The transgenic plants were confirmed
to be homoplasmic (presence of only transformed genomes) after performing
southern blot analysis with a flanking sequence probe.
The expression of CTB FC AMA-1 and CTB MSP-1 was driven by the psbA
5’UTR in transgenic lines and confirmed by an immunoblot. The proteins were
observed at 27.5 kDa in CTB FC AMA-1 and 23 kDa in CTB MSP-1 in both the
insoluble (pellet) and soluble (supernatant) fractions as seen in Figure 7. Along
with the expression of the CTB-malarial monomer, the immunoblot displayed
other forms such as dimers, trimers, tetramers, and pentamers. The expression
levels in mature leaves of CTB FC AMA-1 and CTB MSP-1 protein reached 6.39.5% and 1.4-2%, respectively as shown in Figure 8. The expression level of
CTB FC AMA-1 and CTB MSP-1 is comparable to CTB-Pins in lettuce of 1.8%
TSP (Ruhlman, Ahangari et al. 2007) but higher levels were seen with 14.8%
accumulation of F1-V (Arlen, Singleton et al. 2008), 14% of anthrax protective
antigen (Koya, Moayeri et al. 2005), and 16% of CTB-Pins in tobacco (Ruhlman,
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Ahangari et al. 2007). Although lower levels of expression were observed with
the chloroplast-derived CTB-malarial proteins in tobacco it still provides a
sufficient level of expression to proceed with animal or preclinical studies
(Ruhlman, Ahangari et al. 2007).
The antigen administered to the mice via a subcutaneous injection was
enriched versus purified because the CTB-malarial protein did not consist of an
epitope tag for the facilitation of purification. CTB is known to bind to immobilized
nickel ions (Dertzbaugh and Cox 1998) and this lead to enriching the CTBmalarial antigen in plant extracts using nickel beads. The CTB-malarial antigens
were successfully enriched with nickel beads and to ensure adequate amounts
for immunization studies, immobilized metal affinity chromatography using Talon
Superflow Metal Affinity Resin was used.

The oral-deliverable plant material

administered to mice was done via oral gavage.
Majority of vaccines use the needle-based subcutaneous injection method
but delivering the antigen via the oral route is a possibility.

Following

immunization, the immune titers of the mice were determined for mice receiving
the antigen via the injectable route versus oral boosts. Immunization studies
confirmed the chloroplast-derived malarial antigens were immunogenic with
respect to anti-CTB and anti-MSP-119 antibodies (Figure 12 and Table 2). The
titers of groups 3 and 4 in regards to anti-AMA-1 titers were not completed
because of the lack of AMA-1 protein. Also, the MSP-1 titers of groups 7 and 8
were not completed because of the lack of adequate amounts of MSP-1 protein.
CTB was fused with the malarial antigens because of it’s potential of acting as an
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oral-mucosal adjuvant (Holmgren, Lycke et al. 1993) and also possibly
enhancing the immune response (Daniell, Lee et al. 2001). The mice were found
to be immunogenic in regards to CTB and the IgG1 titers ranged from 0 –
1:800,000 with higher titers in bleeds #3, #4, and #5. High titers were observed
in experimental groups besides group 4 (oral delivery CTB FC AMA-1) and a
likely reason for low IgG1 titers is because CTB IgA sera titers were significantly
higher possibly suppressing the synthesis of IgG1 in these mice (data not
shown). Mice titers for IgG1 MSP-119 ranged from 0 – 1:50,000 with higher titers
in bleeds #3, #4, and #5 and higher titers in group 5 CTB MSP-1 (subcutaneous
injection) versus group 6 (oral delivery). Several mice showed no detectable
MSP-119 titers (two mice each in group 5 and 6) with ELISA analysis (Table 2)
and a likely explanation is not every mouse responds to the same antigen in the
same manner but these mice showed similar CTB titers in comparison with the
other mice in the group. Higher titers were observed in group 5 compared to
group 6 because of the challenge to deliver the exact amount of antigen in oral
gavage to every mouse and titers are expected to be higher when antigen is
directly introduced into the immune system via an injection. A reason why the
titers for MSP-1 were significantly lower than CTB titers may be because malarial
antigens generally display poor immunogenicity even with the use of an adjuvant
(Sachdeva, Mohmmed et al. 2006).

Several strategies for optimizing

immunogenicity of malarial antigens include the use of different adjuvants,
optimizing immunization protocols, using rabbits or monkeys for animal model
testing, fusing exogenous viral or bacterial antigens, or constructing multivalent
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antigen chimeras (Pan, Huang et al. 2004; Qian, Wu et al. 2007; Greenwood,
Fidock et al. 2008). The Pf chimeric protein 2.9 (PfCP-2.9) consisting of domain
III of AMA-1 and 19-kDa C-terminal fragment of MSP-1 was found to be highly
immunogenic in rabbits and rhesus monkeys by inducing 11 to 18 fold higher
titers than the individual antigens alone (Pan, Huang et al. 2004).

IFA and

immunoblots confirmed the presence of anti-AMA-1 and MSP-1 antibodies in the
sera of immunized mice because of the recognition of parasite and parasite
protein, as shown in Figures 13, 14. In the immunoblot analysis, both anti-AMA1 and anti-MSP-1 antibodies recognized the ring and schizont stages and this
follows the expression profiles of AMA-1 and MSP-1 provided by PlasmoDB.
The same volume of the sera was used for both immunoblots but the intensity
was greater with using anti-MSP-1 antibodies and this may be due to the titer of
the mouse immunized with MSP-1 was higher than the mouse immunized with
AMA-1. AMA-1 titers were not determined because of the lack of AMA-1 protein
for ELISA analysis.
To investigate if the AMA-1 and MSP-1 antibodies mice generate after
immunization prevents parasite invasion into RBCS, an in vitro parasite inhibition
assay was performed. If anti-AMA-1 and anti-MSP-1 antibodies are present in
the sera collected from immunized mice there should be a decrease in
parasitemia indicating the inhibition of the parasites from invading RBCs. In the
control groups, sera from unimmunized mice and mice immunized with wild type
leaf material or adjuvant only, similar levels of parasitemia were observed
compared to control wells incubated with no sera (Table 3). The relative percent
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of inhibition in comparison to the positive control (MRA-35 PfMSP1-19) was
determined for all control and experimental groups because the highest percent
of inhibition observed for the positive control was 53%. In comparison to the
positive control, relative percent of inhibition was found to be the highest in group
five, subcutaneous CTB MSP-1, (117.2%, Table 3). Direct correlation of mouse
titers and percent of parasite inhibition of invasion into RBCs was observed with
a mouse with a high MSP-119 titer (1:50,000, Table 2) resulting in the greatest
percent of inhibition (63.6%) in comparison with a mouse with lower titer
(1:1,000, Table 2) resulting in only 47% inhibition (Table 4). Other studies have
found higher percentages of inhibition (Pan, Huang et al. 2004; Arnot, Cavanagh
et al. 2008) but they incubated parasite culture with purified IgG or isolated
specific antibodies and did not use whole sera. A positive control, antibody from
MR4 (MRA-35 PfMSP1-19), was included in the assay to achieve the greatest
possible percent of inhibition but only resulted in 53%. The positive control has
no known published antibody titer and since it was produced in rabbit the titer
was not determined because the titer cannot be directly correlated with the titer
of the immunized mice because the lack of a comparative secondary antibody.
The results provided from the positive control inefficiently prevented the maximal
percent of invasion, which proceeded to the experimentation of using different
dilutions of the antibody and examining a direct comparison of parasitemia levels.
The most diluted concentration of antibody resulted in about half of the percent of
inhibition compared to the antibody incubated with the parasite culture at 20%
(Table 5). Both in vitro parasite inhibition assays displayed greater inhibition with
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higher immune titers or antibody concentration compared to lower titers and
concentration of antibody with less inhibition.

Although the in vitro inhibition

assay provided evidence that the antibodies generated from mice were effective
in preventing parasite invasion of RBCs, a more accurate quantification needs to
be assessed by using an appropriate animal model and a lethal parasite
challenge (Sachdeva, Mohmmed et al. 2006) because the mice were challenged
with a rodent malaria strain (Plasmodium berghei) that was generated to express
the P. falciparum form of MSP-119 (de Koning-Ward, O'Donnell et al. 2003) and
the challenge was unsuccessful.

One report was found to be successful in

protecting the mice after the parasite challenge with the P. berghei/P. falciparum
chimeric line (Pb-PfM19) but they passively immunized the mice with antiPfMSP-142 IgG purified from rabbit sera before parasite challenge instead of
using active immunization (Sachdeva, Mohmmed et al. 2006).
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CONCLUSIONS
Malaria is a prominent vector-borne parasitic disease and severe public
health problem globally, especially prevalent in poor-developing countries. There
is a great need to create a low cost human malarial vaccine with the elimination
of laborious purification techniques and technical skills. Two leading blood stage
malarial vaccine candidates AMA-1 and MSP-1 were constructed in a fusion
cassette with CTB. The CTB-malarial antigens were expressed in tobacco plants
via plastid transformation and accumulated to high to moderate levels in CTB FC
AMA-1 and CTB-MSP-1 to 9.5% and 2% of the total soluble protein, respectively.
The chloroplast-derived CTB-malarial proteins were administered to mice by
subcutaneous injection and oral gavage. The immunogenicities of the CTB and
MSP-119 antigens were determined to be in the range of 1:1000 – 1:800,000 and
1:100 – 1:50,000 in mice titers, respectively. To maximize the MSP-1 titers in
oral delivery of CTB MSP-1, there needs to a better approach on delivering the
same quantity of antigen to every mouse. Sera collected from mice immunized
with both CTB FC AMA-1 and CTB MSP-1 was found to recognize native
parasite and native parasite protein via IFA and immunoblot analysis, indicating
anti-AMA-1 and anti-MSP-1 antibodies were generated in immunized mice. Antimalarial antibodies were found to inhibit parasite invasion into erythrocytes with
sera collected from immunized mice. The lack of an appropriate animal model
needs to be established before in vivo challenge and protection can be
investigated. Results of these investigations may lead to further experimentation
in malarial vaccine development with other malarial antigens and in edible crops.
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